Esperion Therapeutics Inc
- Country
- ๐จ๐ทCosta Rica
- Ownership
- Public
- Established
- 1998-01-01
- Employees
- 240
- Market Cap
- $335.5M
- Website
- http://www.esperion.com
Milk-Only Lactation Study to Evaluate the Concentration of Bempedoic Acid and Bempedoic Acid/Ezetimibe Fixed Combination Drug Product (FCDP) in the Breast Milk of Healthy Lactating Women
- Conditions
- Interventions
- First Posted Date
- 2023-09-01
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- Esperion Therapeutics, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT06021951
- Locations
- ๐บ๐ธ
PPD Development, Las Vegas Research Unit, Las Vegas, Nevada, United States
A Phase 2 Clinical Study in Children With HeFH Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing
- First Posted Date
- 2023-01-23
- Last Posted Date
- 2023-08-09
- Lead Sponsor
- Esperion Therapeutics, Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT05694260
- Locations
- ๐ช๐ธ
Hospital Sant Joan de Deu, Barcelona, Spain
๐จ๐ฆMcMaster University Medical Center, Hamilton, Ontario, Canada
๐บ๐ธContinental Clinical Solutions, Towson, Maryland, United States
Bempedoic Acid Pregnancy Surveillance Program
- Conditions
- First Posted Date
- 2021-11-02
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Esperion Therapeutics, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT05103254
- Locations
- ๐บ๐ธ
Evidera, PPD business unit, Morrisville, North Carolina, United States
Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-C
- First Posted Date
- 2018-05-22
- Last Posted Date
- 2020-04-09
- Lead Sponsor
- Esperion Therapeutics, Inc.
- Target Recruit Count
- 242
- Registration Number
- NCT03531905
- Locations
- ๐บ๐ธ
Clinical Trials Research, Lincoln, California, United States
๐บ๐ธFInlay Medical Research, Miami, Florida, United States
๐บ๐ธL-MARC Research Center, Louisville, Kentucky, United States
A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy
- Conditions
- Interventions
- First Posted Date
- 2017-11-08
- Last Posted Date
- 2020-04-08
- Lead Sponsor
- Esperion Therapeutics, Inc.
- Target Recruit Count
- 382
- Registration Number
- NCT03337308
- Locations
- ๐บ๐ธ
Foundation Cardiology, Nashua, New Hampshire, United States
๐บ๐ธPMG Research of Knoxville, Knoxville, Tennessee, United States
๐บ๐ธPMG Research of McFarland, Ames, Iowa, United States
Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg When Added to PCSK9 Inhibitor Therapy
- Conditions
- Interventions
- First Posted Date
- 2017-06-20
- Last Posted Date
- 2020-04-03
- Lead Sponsor
- Esperion Therapeutics, Inc.
- Target Recruit Count
- 59
- Registration Number
- NCT03193047
- Locations
- ๐บ๐ธ
L-MARC Research Center, Louisville, Kentucky, United States
Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE)
- Conditions
- Interventions
- First Posted Date
- 2017-03-01
- Last Posted Date
- 2021-03-01
- Lead Sponsor
- Esperion Therapeutics, Inc.
- Target Recruit Count
- 1462
- Registration Number
- NCT03067441
- Locations
- ๐บ๐ธ
Jedidiah Clinical Research, Tampa, Florida, United States
๐บ๐ธL-MARC Research Center, Louisville, Kentucky, United States
๐บ๐ธSentral Clinical Research Services, Cincinnati, Ohio, United States
Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-C
- Conditions
- Interventions
- First Posted Date
- 2017-02-13
- Last Posted Date
- 2020-04-03
- Lead Sponsor
- Esperion Therapeutics, Inc.
- Target Recruit Count
- 63
- Registration Number
- NCT03051100
- Locations
- ๐บ๐ธ
PMG Research of Rocky Mount, Rocky Mount, North Carolina, United States
๐บ๐ธPMG Research of Raleigh, Raleigh, North Carolina, United States
๐บ๐ธHampton Roads Center for Clinical Research, Virginia Beach, Virginia, United States
Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility)
- Conditions
- Interventions
- First Posted Date
- 2016-12-22
- Last Posted Date
- 2020-05-11
- Lead Sponsor
- Esperion Therapeutics, Inc.
- Target Recruit Count
- 269
- Registration Number
- NCT03001076
Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo
- Conditions
- Interventions
- First Posted Date
- 2016-12-15
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- Esperion Therapeutics, Inc.
- Target Recruit Count
- 13970
- Registration Number
- NCT02993406
- Locations
- ๐บ๐ธ
Seton Heart Institute, Austin, Texas, United States